WASHINGTON (Reuters) - AstraZeneca Plc is urging U.S. lawmakers to revive a program for drugmakers who want to voluntarily submit their television commercials for regulatory review, according to a ...
AstraZeneca reported $45.8bn in revenues for 2023, a 6% gain from the previous year on a CER basis. EPS of $7.26 was up 15% year-over-year. The company's oncology division accounted for 37% of total ...
A data and safety monitoring board formed by the National Institute for Allergy and Infectious Diseases made a rare move when it published a statement March 23 saying AstraZeneca's March 22 ...
Patients and caregivers may be one step closer to having the ability to give themselves or someone else a flu vaccine without having to go to a pharmacy or clinic. The Food and Drug Administration ...
The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...
On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously ...
(Reuters) -A combination of AstraZeneca's blockbuster cancer drug Tagrisso, with chemotherapy to treat a type of lung cancer, has been accepted and granted priority review by the U.S. Food and Drug ...
Investing.com -- AstraZeneca ’s new drug application for baxdrostat has been accepted for priority review by the US Food and Drug Administration (FDA) to treat adults with hard-to-control hypertension ...
AstraZeneca's baxdrostat heads into FDA review after Phase 3 data showed strong blood pressure reductions in adults with hard ...
In a move to enhance its cancer drug pipeline, AstraZeneca agreed to pay up to $6.9 billion to a Japanese drugmaker for the shared rights to a new cancer drug, according to The Wall Street Journal.
Nov 1 (Reuters) - AstraZeneca Plc (AZN.L), opens new tab said on Sunday Britain's health regulator had started an accelerated review of its potential coronavirus vaccine. "We confirm the MHRA's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback